Tatsis Ourania sold VERV

July 25, 2025 · Form 4 insider transaction

Tatsis Ourania sold 42,200 shares of Verve Therapeutics Inc, a transaction worth N/A. The trade was recorded as disposition to the issuer and disclosed on an SEC Form 4, filed 3 days after the transaction.

Direction
Disposed (sell-side)
Shares
42,200
Price
N/A
Total value
N/A
RoleDirector
SecurityStock Option (right to buy)
Transaction codeD: Disposition to the issuer
Transaction dateJuly 25, 2025
Filing dateJuly 28, 2025
Shares owned after0
OwnershipDirect
10b5-1 planNo
AmendedNo

Footnotes

Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the; (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting).

View the original Form 4 on SEC EDGAR